Margarida Maia, PhD,  science writer—

Having microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) — the two most common types of ANCA-associated vasculitis (AAV) — better determines patients’ clinical features and outcomes than the type of AAV-driving, self-reactive antibodies they have. That’s according to a study in Spain that showed that GPA was an…

ANCA-associated vasculitis (AAV) patients receiving a cumulative dose of at least 935 mg of glucocorticoids over six months are more likely to see clinically meaningful side effects, according to a study using calculations based on the Glucocorticoid Toxicity Index (GTI). The findings suggest the GTI, which considers the frequency…

Recruitment is continuing in three countries for a Phase 1b/2a clinical trial testing Alpine Immune Sciences’ povetacicept in adults with autoimmune conditions affecting the kidneys, including ANCA-associated vasculitis (AAV). Called RUBY-3 (NCT05732402), the early study is designed to enroll an estimated 56 patients, ages 18 and older,…

The Renal Risk Score may be a better histopathologic classification model than Berden for predicting long-term loss of kidney function in people with ANCA-related vasculitis (AAV) who have glomerulonephritis, an inflammation of the kidneys’ filtering units, a study finds. Incorporating the renal risk score into clinical decision-making could help…

The Kidney Disease: Improving Global Outcomes (KDIGO) work group has released an updated practice guideline based on developments in how best to manage ANCA-associated vasculitis (AAV) associated with inflammation or damage to the kidneys. The guideline now offers advice on the use of lower doses of…

Tavneos (avacopan) improved kidney function and reduced the need for the glucocorticoid prednisone in four older patients who had signs of kidney failure due to ANCA-associated vasculitis (AAV), researchers in Canada report. While Tavneos may help patients enter into remission without the harmful side effects of glucocorticoids, “more…

Certain clotting markers are found at higher levels in the blood of people with ANCA-associated vasculitis (AAV) when their disease is active than when it’s in remission and symptoms ease or disappear, a study finds. Too much clotting may explain why people with active AAV are at increased risk…

A higher eosinophil count at diagnosis is linked to more severe disease activity in people with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis (AAV), a study suggests. Counting eosinophils, white blood cells that usually release enzymes and other molecules in…

Evotec has formed a partnership with Charité – Universitätsmedizin Berlin in Germany to build a database of all sorts of molecular information from people with ANCA-associated vasculitis (AAV). Molecular profiles, a kind of fingerprint of AAV, may help scientists better understand the autoimmune disease and pave the way…

Factor XII (FXII), a protein involved in blood clotting, is found at significantly higher levels in the blood of people with active ANCA-associated vasculitis (AAV) relative to those in clinical remission, or whose symptoms have eased or disappeared. That’s according to a study in China that also found that…